GENEVA--(BUSINESS WIRE)--Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today the signing of a commercial license agreement that provides ImmuNext, Inc. with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform™ to advance the development of ImmuNext’s anti-CD40 ligand (CD40L) antibody. ImmuNext is developing this antibody for treatment of chronic autoimmune disorders with high unmet medical need, such as lupus, inflammatory bowel disease and multiple sclerosis.
CD40L (also called CD154) is a highly validated, superlative therapeutic target in autoimmunity and graft rejection. CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF family of molecules. It binds to CD40 on antigen-presenting cells, which leads to many effects depending on the target cell type.
“We are pleased to expand our relationship with ImmuNext, which began out of a necessity to rapidly and predictably develop a high productivity cell line that would meet ImmuNext’s demand projections in the event of a successful clinical development and commercial launch of their anti-CD40L antibody,” said Yemi Onakunle, PhD, vice president, licensing and business development, Selexis SA. “ImmuNext’s development program received a $1.8M Small Business Innovation and Research (SBIR) Phase 2B award from the National Institutes of Health earlier this year for pre-clinical development of its proprietary anti-CD40L antibody. The Selexis team is proud to have played a small role in helping the company to advance its research and secure such an important award that will help to meet unmet medical need.”
Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.
About Selexis SA
Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 95 partners worldwide, nearly 80 drug products in clinical manufacturing and two commercial products utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.
FOR MORE INFORMATION